When marginal zone lymphoma stops responding to standard treatment or returns after a period of remission, patients and their medical teams face a challenging situation that requires careful planning and access to both established therapies and emerging treatment options being tested in clinical research studies.

Finding the Right Path When Lymphoma Persists or Returns

Marginal zone lymphoma is considered a slow-growing form of non-Hodgkin lymphoma, which is a cancer affecting white blood cells called lymphocytes. The disease develops in specific areas called marginal zones found at the edges of lymphoid tissues throughout the body. Most patients live many years with this condition, often longer than ten years, and many respond well to initial treatments.^[1]

However, for some patients, the lymphoma does not respond as hoped to the first treatment, or it comes back after a period during which it seemed controlled. When doctors say a lymphoma is refractory, they mean it does not respond to treatment at all or the response is very brief. When they say it has relapsed, they mean the disease has returned after a period when tests showed no signs of cancer. About one in five patients with marginal zone lymphoma experience relapse or disease progression within two years of starting treatment, and these individuals face a more difficult situation, with median survival dropping to only three to five years instead of more than ten.^[1]

The goal of treatment for relapsed or refractory marginal zone lymphoma is to bring the disease back under control, reduce symptoms, extend survival, and improve quality of life. Treatment choices depend on several factors, including which treatments were used before, how long the remission lasted, the patient’s age and overall health, and whether the patient is experiencing symptoms such as fatigue, weight loss, or swollen lymph nodes.^[2]

For patients whose disease has returned or proven resistant to treatment, doctors may choose from the same therapies used for newly diagnosed disease, or they may recommend newer targeted drugs that have been developed specifically for difficult-to-treat cases. The medical community continues to search for better options because current treatment choices remain limited.^[1]

Standard Treatment Approaches for Difficult-to-Treat Disease

When marginal zone lymphoma returns or does not respond to initial therapy, doctors often turn to treatments that combine an immunotherapy drug called rituximab with various chemotherapy drugs. Rituximab is a type of medicine known as an anti-CD20 monoclonal antibody. It works by attaching to a protein called CD20 that sits on the surface of lymphoma cells, marking them for destruction by the immune system.^[1]

One commonly used combination is known as R², which pairs rituximab with an immunomodulator drug called lenalidomide (sold under brand names Rituxan and Revlimid). This combination is frequently recommended for patients whose lymphoma has come back after previous treatment.^[2] Lenalidomide helps the immune system work better against cancer cells and may also directly affect how cancer cells grow and survive.

Another standard approach involves bendamustine, a chemotherapy drug, combined with rituximab. This pairing is often referred to as BR. Bendamustine damages the DNA inside cancer cells, preventing them from dividing and growing. When combined with rituximab, the two drugs attack the lymphoma through different mechanisms, potentially improving effectiveness.^[8]

For more advanced or aggressive cases, doctors may recommend stronger chemotherapy combinations such as R-CHOP, which stands for rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Each of these chemotherapy drugs works in a different way to damage cancer cells and prevent their growth. Cyclophosphamide and doxorubicin damage cancer cell DNA, vincristine prevents cells from dividing by disrupting their internal structure, and prednisone is a steroid that reduces inflammation and can help kill lymphoma cells.^[8]

Another option is R-CVP, which is similar to R-CHOP but uses a different set of chemotherapy drugs combined with rituximab. Some patients receive chlorambucil, an older chemotherapy drug, paired with rituximab. The choice among these combinations depends on factors like the patient’s age, overall fitness, previous treatments received, and how well their organs, particularly the heart and kidneys, are functioning.^[8]

Radiation therapy may also play a role in treating relapsed or refractory marginal zone lymphoma, especially when the disease is limited to one or a few specific areas of the body. This approach uses high-energy rays to damage cancer cells in the targeted region, potentially shrinking tumors and relieving symptoms caused by enlarged lymph nodes.^[8]

Treatment duration varies depending on the specific drugs used and how the patient responds. Chemotherapy is typically given in cycles, with periods of treatment followed by rest periods to allow the body to recover. A full course may span several months. Side effects from these treatments can include fatigue, nausea, increased risk of infections due to low white blood cell counts, hair loss, numbness or tingling in the hands and feet, and increased bruising or bleeding due to low platelet counts. Rituximab can cause infusion reactions such as fever, chills, and low blood pressure during or shortly after the medication is given.^[1]

Novel Therapies Being Tested in Clinical Trials

Because treatment options for relapsed or refractory marginal zone lymphoma remain limited, researchers have been working to develop and test new drugs. These investigational treatments represent hope for patients whose disease has not responded to standard therapies or who have exhausted available options.

Bruton’s Tyrosine Kinase Inhibitors

One of the most promising classes of new drugs being studied is called Bruton’s tyrosine kinase inhibitors, or BTK inhibitors for short. These drugs work by blocking a specific enzyme inside lymphoma cells that is essential for their survival and growth. BTK plays a key role in the signaling pathway that tells B cells (the type of white blood cell from which marginal zone lymphomas develop) to grow and multiply.^[7]

Ibrutinib was the first BTK inhibitor approved specifically for treating relapsed or refractory marginal zone lymphoma. This approval came in 2017 based on results from a Phase II clinical trial, which is a type of study designed to evaluate whether a drug is effective and to gather more information about its safety. In this trial, ibrutinib produced an overall response rate of 48%, meaning that nearly half of patients experienced shrinkage of their lymphoma. Complete responses, where all signs of lymphoma disappeared, occurred in 3% of patients. The median progression-free survival—the time before the disease started growing again—was 14.2 months.^[7]

Zanubrutinib is another BTK inhibitor that has been studied and approved for use in relapsed or refractory marginal zone lymphoma. Like ibrutinib, zanubrutinib blocks the BTK enzyme, but it is designed to be more selective, potentially leading to fewer side effects. It is also recommended as a treatment option for patients whose disease has returned or not responded to previous therapy.^[2][8]

BTK inhibitors are taken as pills daily and work by continuously blocking the enzyme that lymphoma cells need to survive. Common side effects can include diarrhea, fatigue, muscle aches, increased risk of infections, bruising, and bleeding. Some patients also experience irregular heartbeat (atrial fibrillation), so doctors monitor heart function during treatment.^[7]

Novel Immunomodulatory Drugs

Researchers are also investigating drugs that modify the immune system’s response to cancer. Lenalidomide, mentioned earlier as part of standard treatment, belongs to this class. It works through multiple mechanisms: it directly affects cancer cells, enhances the body’s immune response against tumors, and may prevent the formation of new blood vessels that tumors need to grow.^[1]

When combined with rituximab (the R² regimen), lenalidomide has shown promising results in clinical trials. Studies have evaluated this combination both for newly diagnosed patients and those with relapsed disease, examining whether it can achieve good response rates while causing manageable side effects. The combination takes advantage of both drugs’ different mechanisms to attack lymphoma cells more effectively.^[2]

Next-Generation Monoclonal Antibodies

While rituximab remains the most widely used monoclonal antibody for treating marginal zone lymphoma, scientists are developing newer versions that may work better or cause fewer side effects. These novel anti-CD20 monoclonal antibodies are designed to bind more strongly to lymphoma cells or to trigger a more powerful immune response against them.^[1]

Some of these experimental antibodies are being tested in Phase I trials (early studies focused on safety) and Phase II trials (studies focused on effectiveness) in patients with various types of indolent lymphomas, including marginal zone lymphoma. The goal is to determine whether these newer antibodies can produce better outcomes than rituximab or help patients who have stopped responding to rituximab.^[1]

Small Molecule Kinase Inhibitors

Beyond BTK inhibitors, researchers are studying other small molecule kinase inhibitors that target different enzymes involved in lymphoma cell growth and survival. These drugs work by interfering with specific signaling pathways inside cancer cells, essentially cutting off the signals that tell the cells to grow, divide, and survive.^[1]

Scientists have identified that pathways regulating NFkB (a protein complex that controls gene expression related to immune response and cell survival) play important roles in marginal zone lymphoma. Drugs targeting these pathways are being evaluated in clinical trials to see if they can effectively treat patients whose disease has become resistant to other therapies.^[7]

Understanding Clinical Trial Phases

When reading about new treatments, it helps to understand what the different phases of clinical trials mean. Phase I trials are the first tests in humans, focusing primarily on safety and determining the right dose. Phase II trials evaluate whether the drug works against the disease and continue to monitor safety in a larger group of patients. Phase III trials compare the new drug directly to standard treatment in even larger groups to determine if it is better, and these trials often lead to drug approval if results are positive.^[1]

Clinical trials for relapsed or refractory marginal zone lymphoma are being conducted in multiple countries, including the United States, Europe, and parts of Asia. Eligibility for these trials depends on factors such as previous treatments received, disease characteristics, overall health status, and organ function. Patients interested in clinical trials should discuss options with their healthcare team, who can help determine if any appropriate studies are available.^[1]

Most common treatment methods

• Targeted therapy with monoclonal antibodies
  • Rituximab (Rituxan and biosimilars) alone or combined with other drugs, works by attaching to CD20 protein on lymphoma cells
  • Novel anti-CD20 monoclonal antibodies being tested in clinical trials for potentially improved effectiveness
• BTK inhibitors (small molecule targeted drugs)
  • Ibrutinib (Imbruvica), approved for relapsed/refractory disease, blocks Bruton’s tyrosine kinase enzyme
  • Zanubrutinib (Brukinsa), also approved for relapsed/refractory disease, potentially more selective targeting
• Immunomodulatory therapy
  • Lenalidomide (Revlimid) combined with rituximab (R² regimen), enhances immune response and directly affects cancer cells
• Chemotherapy combinations
  • BR – bendamustine and rituximab, damages cancer cell DNA while marking cells for immune destruction
  • R-CHOP – rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, multi-drug combination attacking cancer through different mechanisms
  • R-CVP – rituximab, cyclophosphamide, vincristine, prednisone, alternative combination for patients unable to tolerate stronger regimens
  • Chlorambucil and rituximab, older chemotherapy option suitable for some patients
  • Cyclophosphamide and rituximab alone
• Radiation therapy
  • External beam radiation targeted to specific areas where lymphoma is present, particularly useful for localized disease
• Watch and wait (active surveillance)
  • Careful monitoring without immediate treatment for slow-growing disease without symptoms